Table 2.
Clinical characteristics of patients in the short-, and long-wait groups.
| Varible | All patients (n = 158) | SWT (days) Short ≤60 (n = 120) | Long >60 (n = 38) | P |
|---|---|---|---|---|
| Age (yr) | 68 (61-74) | 68 (61-74) | 67 (60-73) | 0.763 |
| Sex | 0.241 | |||
| Male | 91 | 66 (41.8%) | 25 (15.8%) | |
| Female | 67 | 54 (34.2%) | 13 ( 8.2%) | |
| Smoke | 0.269 | |||
| Yes | 28 | 19 (12.0%) | 9 ( 5.7%) | |
| No | 130 | 101 (63.9%) | 29 (18.4%) | |
| ECOG performance status | 0.755 | |||
| 0 | 99 | 76 (48.1%) | 23 (14.6%) | |
| 1 | 59 | 44 (27.8%) | 15 ( 9.5%) | |
| Median Body mass index (kg/m2) | 21.4 (19.3-23.5) | 22.5 (20.4-24.7) | 23.2 (19.5-25.2) | 0.123 |
| Haematuria | 0.000 | |||
| (+) | 95 | 61 (38.6%) | 34 (21.5%) | |
| (−) | 63 | 59 (37.4%) | 4 ( 2.5%) | |
| Tumor location | 0.166 | |||
| Renal pelvis | 106 | 84 (53.2%) | 22 (13.9%) | |
| Ureter | 52 | 36 (22.8%) | 16 (10.1%) | |
| Tumor grade | 0.952 | |||
| High | 120 | 91 (57.5%) | 29 (18.4%) | |
| Low | 38 | 29 (18.4%) | 9 ( 5.7%) | |
| Tumor size | 3.5 (2.5-5.5) | 3.5 (2.5-5.5) | 3.5 (3.0-5.0) | 0.886 |
| Amount of lesions | 0.199 | |||
| Single | 134 | 102 (64.6%) | 32 (20.3%) | |
| Mutiple | 24 | 18 (11.4%) | 6 ( 3.7%) | |
| pT stage | 0.866 | |||
| ≤pT1 | 36 | 28 (17.7%) | 8 ( 5.1%) | |
| pT2 | 66 | 48 (30.4%) | 18 (11.4%) | |
| pT3 | 45 | 35 (22.1%) | 10 ( 6.3%) | |
| pT4 | 11 | 9 ( 5.7%) | 2 ( 1.3%) | |
| Lymph node involvement | 0.867 | |||
| pN0 | 138 | 105 (66.4%) | 33 (20.9%) | |
| pN+ | 20 | 15 ( 9.5%) | 5 ( 3.2%) | |
| LND | 0.490 | |||
| Yes | 51 | 37 (23.4%) | 14 ( 8.9%) | |
| No | 107 | 83 (52.5%) | 24 (15.2%) | |
| Surgical approach | 0.488 | |||
| Open | 43 | 31 (19.6%) | 12 ( 7.6%) | |
| Laparoscopy | 115 | 89 (56.3%) | 26 (16.5%) |
ECOG, Eastern Cooperative Oncology Group.